Related Experiment Videos
Depression of cardiac function by bisantrene
Southern Medical Journal
|December 1, 1985
Summary
Bisantrene, a novel chemotherapy, may cause heart problems despite earlier beliefs. This study observed potential cardiac function declines in children, necessitating further research into its cardiotoxicity.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Bisantrene is an anthracycline derivative in phase 2 trials.
- It was presumed to be free of cardiotoxic effects.
Observation:
- A case of congestive heart failure after bisantrene infusion in a child.
- A second child showed transient cardiac function declines post-infusion.
Findings:
- Bisantrene may acutely depress myocardial contractile function.
- Potential cardiotoxicity of bisantrene requires further investigation.
Implications:
- Clinical monitoring for cardiac function is crucial during bisantrene therapy.
- Further studies are needed to fully characterize bisantrene's cardiac safety profile.